TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion criteria:~* Histologically confirmed non-small cell lung cancer~  * Stage I-IIIA disease~* Must have undergone a complete resection~* Must begin adjuvant chemotherapy within 8 weeks of surgical resection~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm\^3~* Hemoglobin ≥ 8.0 g/dL~* Platelet count ≥ 100,000/mm\^3~* Serum creatinine normal OR creatinine clearance ≥ 40 mL/min~* Bilirubin normal~* Alkaline phosphatase (AP), Aspartate aminotransferase (AST), and Alanine transaminase (ALT) must meet 1 of the following criteria:~  * AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)~ * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN~ * AP ≤ 5 times ULN AND AST and ALT normal~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 3 months after study therapy~Exclusion criteria:~* Patients with a history of severe hypersensitivity to docetaxel or polysorbate 80 are excluded.~* Women who are currently or planning to breast feed.~* Those with peripheral neuropathy ≥ grade 2~PRIOR CONCURRENT THERAPY:~* 2-8 weeks since prior surgery and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm Trial (Type: OTHER): adjuvant carboplatin plus docetaxel carboplatin area under curve (AUC) = 6 IV on day 1 every 3 weeks for 4 cycles docetaxel 75 mg/m² IV on day 1 every 3 weeks for 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with primary open angle glaucoma or ocular hypertension~* Provided signed, written informed consent~* 20 years of age and older~* If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study.~Exclusion Criteria:~* Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.~* Presence of any abnormality or significant illness that could be expected to interfere with the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): DE-111 ophthalmic solution
- 2 (Type: ACTIVE_COMPARATOR): Tafluprost ophthalmic solution 0.0015%
- 3 (Type: ACTIVE_COMPARATOR): Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 to 80 years old.~2. Able to provide written informed consent.~3. Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)~4. A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke (CHADS2) index score of at least 2~Exclusion Criteria:~1. Subjects with mitral valve disease or previous valvular heart surgery~2. Known contraindication to any anticoagulant including vitamin K antagonists such as warfarin~3. Known or suspected hereditary or acquired bleeding or coagulation disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): DU-176b 30mg tablet once daily
- 2 (Type: EXPERIMENTAL): DU-176b 60mg once daily
- 3 (Type: EXPERIMENTAL): DU-176b 30mg b.i.d.
- 4 (Type: EXPERIMENTAL): DU-176b 60mg tablets two times a day
- 5 (Type: ACTIVE_COMPARATOR): warfarin tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Critically ill male or female subjects 18 years or older who have a baseline gastric aspirate pH less then or equal to 4~* Subjects admitted to an ICU requiring mechanically ventilated~* Subjects will have at least one additional stress ulcer risk factor~Exclusion Criteria:~* Anticipated use of pre-pyloric enteral feeding after screening until the end of study~* Physician estimated survival of less then 96 hours~* Anticipation of major surgery within 96 hours of study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improve Glaucoma Medication Adherence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open angle glaucoma \[primary open angle glaucoma, pigment dispersion glaucoma, pseudoexfoliation glaucoma, combined mechanism glaucoma, low tension glaucoma\] recorded in the medical record~* Prescribed glaucoma eye drops,~* Visual field performed within the last 9 months.~  * As visual field testing is standard care glaucoma and the investigators wish to establish baseline glaucoma severity, the investigators will require that subjects have a visual field test documented in the chart within 9 months of enrollment.~Exclusion Criteria:~Exclusion criteria for patients At Screener:~* How confident are you that you always remember to use your glaucoma medications?~  * not at all confident~ * somewhat confident~ * very confident)~* And In the past 4 weeks, did you ever forget to take your medicine?~  * Veterans who respond both very confident and no, respectively, will be excluded~Inclusion criteria for companions at screener:~* Willing to participate in assisting the patient with glaucoma drops and~* Willing to accompany the patient to the intervention visit for participants in the intervention arm or eye health education visit for participants in the control arm.~Exclusion criteria for companions: Unable or unwilling to attend baseline visit and intervention or control arm educational session with patient participant.~Exclusion criteria for patients or companions:~* Lacks proficiency in English,~* Lacks either a cell phone or landline phone.~Exclusion criteria for patients post randomization:~* Decision by patient and provider to cease glaucoma medication use~* Change in functional status such that the drops are no longer administered by the patient or the companion (such as nursing home care)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened.
- Control (Type: ACTIVE_COMPARATOR): Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a Step-Up Versus a Step-Down Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of a new episode of dyspepsia, defined as episodic or persistent symptoms including abdominal pain or discomfort and which are, in the opinion of the general practitioner, referable to the upper gastrointestinal tract.~* Over 18 years of age~* Informed consent (written) given.~Exclusion Criteria:~* Use of prescribed acid suppressive medication during 3 months before consult~* Investigated by upper gastrointestinal endoscopy one year before inclusion~* Malignancy~* Contraindication to the study medication~* Pregnancy~* Alarming symptoms like weight loss, bleeding, and disturbed food passage~* Patients with insufficient comprehension of the Dutch language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Step-up (Type: OTHER): Stepwise treatment:~* step1: antacid (+placebo proton pump inhibitor)~* step2: H2-receptor antagonist~* step3: proton pump inhibitor (+ placebo antacid)
- step-down (Type: OTHER): Stepwise treatment:~* step1: proton pump inhibitor (+placebo antacid)~* step2: H2-receptor antagonist~* step3: antacid (+proton pump inhibitor)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who passed at least one year follow up after the procedure.~* Patients who have no symptoms or signs of oncological failure (local recurrence or distant metastasis).~* Presence of NI with normal daytime continence assessed by the Arabic version of short form International Consultation on Incontinence questionnaire (ICIQ-UI Short Form).18~* Normal renal function (eGFR ˃50 ml/min /1.73m2) calculated by the Modification Of Diet in Renal Disease study equation.~* Ability to provide informed consent.~Exclusion Criteria:~* Patients who did not pass one year postoperative.~* Presence of oncological failure.~* Totally continent patient or who has daytime incontinence or chronic urine retention.~* Impaired renal function.~* Uncontrolled DM or hypertension.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tolterodine-treated group (Type: ACTIVE_COMPARATOR): they will receive long acting tolterodine 4 mg at bedtime for 4 weeks. After that re-evaluation. then stop medication for two weeks (washout period).
- placebo-control group (Type: PLACEBO_COMPARATOR): they will receive placebo at bedtime for 4 weeks. After that re-evaluation. then stop for two weeks (washout period). Then re-evaluate the nocturnal incontinence status and crosed over to receive long acting tolterodine 4 mg for 4 weeks. at the end the nocturnal incontinence status will be evaluated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)~* Male or female patients at least 18 years of age at time of informed consent~* T1DM (diagnosed clinically) prior to inclusion in the study, and/or T2DM, insulin using patients (diagnosed clinically) prior to inclusion in the study~* Planned initiation with Tresiba®~Exclusion Criteria:~* Known or suspected hypersensitivity to Tresiba® or any of the excipients listed in Section 6.1 of the SmPC (Summary of Product Characteristics) or related products~* Previous participation in this study (i.e. provision of informed consent)~* Patients who have previously been treated with Tresiba®~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. To meet the new diagnosed type 2 diabetes patients, never received oral hypoglycemic drugs or insulin therapy;~2. In accordance with the nonalcoholic fatty liver (NAFLD) criteria for the diagnosis of patients.~3. the level of HbA1c was 7 -10.0%;~4. age 18-70, body mass index 21-35kg/m2;~5. the subjects informed consent and signed the informed consent.~Exclusion Criteria:~1. type 1 diabetes or secondary diabetes;~2. suffering from other liver diseases, such as hepatitis, self - free liver, etc.~3. abnormal thyroid function (in the active period), or the need for long-term oral and intravenous glucocorticoids to treat patients;~4. patients with severe renal dysfunction or renal disease (eGFR\<60);~5. in those with abnormal liver function, Alanine transaminase(ALT) or Aspartate transaminase(AST) was more than 3 times the normal upper limit.~6. people with serious gastrointestinal diseases such as peptic ulcers and chronic diarrhea;~7. patients with severe cardiopulmonary disease, cerebrovascular disease or stents;~8. hemopoietic system diseases such as serious primary diseases, hemoglobin \< 100g/L or need regular transfusion treatment;~9. pregnant, breast-feeding, women of childbearing age who are unwilling to contraception during the study period;~10. chronic cardiac insufficiency, the classification of heart function III level and above;~11. uncontrolled malignant tumor, and the history of bladder cancer.~12. acute complications of diabetes;~13. the use of other drugs for diabetes and liver disease;~14. patients who had participated in other clinical studies within three months;~15. people who have known allergies to this kind of drugs are known.~16. it is impossible to guarantee the effect or the safety judgment of the drug or the person who is unable to cooperate with the mental illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Combination of Pioglitazone and Metformin Tablets (Type: EXPERIMENTAL): dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
- Metformin Hydrochloride Tablets (Type: ACTIVE_COMPARATOR): dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical history compatible with chronic hepatitis B infection~Other protocol-defined inclusion criteria may apply~Exclusion Criteria:~* Patient is pregnant or breastfeeding~* Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV~* Patient has previously received lamivudine or any investigational anti-HBV nucleoside or nucleotide analog~Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* COVID-19 Confirmed Cases By Means of RT-PCR~* Oxygen saturation (SPO2) ≤ 93% OR respiratory rate ≥ 24~* At least one of the following: Calibrated contactless infrared forehead thermometry temperature of ≥37.8, cough, sputum production, nasal discharge, myalgia, headache or fatigue on admission.~* Time of onset of the symptoms should be acute ( Days ≤ 14)~Exclusion Criteria:~* Refusal to participate expressed by patient or legally authorized representative if they are present~* Patients with prolonged QT or PR intervals, Second or Third Degree heart block, Arrhythmias including torsade de pointes~* Patients using drugs with potential interaction with Hydroxychloroquine + Lopinavir/Ritonavir, Interferon-β 1a، Interferon-β 1b.~* Pregnant or lactating women.~* History of alcohol or drug addiction in the past 5 years.~* Blood ALT/AST levels \> 5 times the upper limit of normal on laboratory results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a (Type: EXPERIMENTAL): None
- Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b (Type: EXPERIMENTAL): None
- Control group: hydroxychloroquine + Lopinavir / Ritonavir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with schizophrenia for more than 1 year and whose symptoms are worsening in the opinion of the investigator~* A total score in the Positive and Negative Syndrome Scale (PANSS) between 70 and 120~* Signed informed consent~* Women must not be pregnant, breastfeeding, and if capable of pregnancy must practice an effective method of birth control~* Men must agree to use a double-barrier method of birth control~* Be medically stable on the basis of clinical laboratory tests, physical examination, medical history, vital signs, and electrocardiogram (ECG)~Exclusion Criteria:~* A diagnosis other than schizophrenia, e.g., dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, primary substance-induced psychotic disorder, dementia-related psychosis~* Relevant history or current presence of any significant or unstable medical condition(s) determined to be clinically significant by the Investigator (ie, obesity, diabetes, heart disease etc)~* A diagnosis of substance dependence within 6 months before screening~* History of neuroleptic malignant syndrome (NMS) or tardive dyskinesia~* Clozapine use in the last 2 months when used for treatment-resistant or treatment-refractory illness~* Clinically significant findings in biochemistry, hematology, ECG or urinalysis results~* Any other disease or condition that, in the opinion of the investigator, would make participation not in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone palmitate 3-month (PP3M) (Type: EXPERIMENTAL): A formulation of paliperidone palmitate with a 3-month injection interval
- Paliperidone palmitate 1-month (PP1M) (Type: ACTIVE_COMPARATOR): A formulation of paliperidone palmitate with a 1-month injection interval

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete